{"id":1015760,"date":"2026-10-30T08:41:49","date_gmt":"2026-10-30T12:41:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/"},"modified":"2026-10-30T08:41:49","modified_gmt":"2026-10-30T12:41:49","slug":"dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/","title":{"rendered":"Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum"},"content":{"rendered":"
\n

\n Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development\u00a0<\/em>\n <\/p>\n

\n Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes and Other Large Chronic-Disease Markets<\/em>\n <\/p>\n

SAN DIEGO, Oct. 30, 2026 (GLOBE NEWSWIRE) — Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced receipt of an additional $1.5 million funding installment under its multi-year grant agreement in support of development of DARE-LARC1, an investigational long-acting reversible contraceptive based on Dar\u00e9 Bioscience’s intelligent drug delivery system (DARE-IDDS) platform.<\/p>\n

With this installment, Dar\u00e9 Bioscience has received a total of approximately $43.3 million in non-dilutive funding under the grant agreement. The remaining approximately $5.6 million of the up to approximately $48.9 million commitment is tied to the future achievement of development and other milestones specified in the grant agreement. The funding will support continued preclinical development of DARE-LARC1, including nonclinical studies, activities intended to support an Investigational New Drug (IND) application, and other program-related work.<\/p>\n

“Every installment we receive under this grant agreement reflects real progress on a program we believe has the potential to meaningfully expand contraceptive choice for women around the world,” said Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Dar\u00e9 Bioscience. “Importantly, this funding does not dilute our shareholders while enabling us to keep advancing DARE-LARC1 toward an IND submission. It also validates development of the DARE-IDDS platform itself, and that validation is the foundation for the strategic discussions to potentially extend the application of this technology into obesity, diabetes and other chronic diseases.”<\/p>\n

\n Extending the DARE-IDDS Platform Beyond Contraception<\/strong>\n <\/p>\n

Dar\u00e9 Bioscience believes the DARE-IDDS platform may have potential beyond women’s health, including with GLP-1 analogs, anti-obesity medications, hormone therapies for areas such as diabetes, breast cancer, and infertility, and neurologic disease treatments such as for Parkinson\u2019s disease, where long-term dosing and treatment burden are central challenges. Many current therapies in these areas rely on frequent injections or daily dosing, and maintaining adherence over months and years can be difficult for patients. A device designed to enable programming not only how much drug is released, but when, could offer an alternative approach. Dar\u00e9 Bioscience is exploring strategic collaborations with companies developing therapies in these areas to evaluate the DARE-IDDS platform in additional indications.<\/p>\n

\n Advancing Long-Acting Contraception<\/strong>\n <\/p>\n

DARE-LARC1 is being developed as a long-acting contraceptive that uses a programmable implantable device (DARE-IDDS) to deliver levonorgestrel over an extended period. By combining an active pharmaceutical ingredient found in several types of contraceptive products with a device designed to control the timing and duration of drug release, the DARE-LARC1 program aims to offer an alternative approach to contraception that would not require daily administration.<\/p>\n

“The DARE-IDDS technology was engineered from the ground up for flexibility, to enable control over not just how much drug is released, but when. That design philosophy is what gives us confidence the platform may have utility in therapeutic areas beyond contraception, and we look forward to generating the data to show it,” commented Annie Thurman, MD, FACOG, Medical Director of Dar\u00e9 Bioscience.<\/p>\n

\n Looking Ahead<\/strong>\n <\/p>\n

Dar\u00e9 Bioscience expects to continue advancing DARE-LARC1 through nonclinical development and activities intended to support a future IND submission. Under the grant agreement, Dar\u00e9 Bioscience\u2019s receipt of additional funding is contingent on achieving specified development milestones and other requirements. The Company is also exploring potential collaborations to evaluate the application of DARE-IDDS in additional therapeutic areas.<\/p>\n

DARE-IDDS is an investigational device in preclinical development. It has not been approved or cleared for clinical investigation in humans or for any use in humans. The DARE-IDDS features described in this press release are based on the results of technological proof-of-concept studies.<\/p>\n

\n
\n ABOUT DAR\u00c9 BIOSCIENCE, INC.<\/u>
\n <\/strong>\n <\/p>\n

Dar\u00e9 Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women\u2019s health between promising science and real-world solutions. Every innovation Dar\u00e9 Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Dar\u00e9 Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to \u201cwait it out\u201d or \u201clive with it,\u201d while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Dar\u00e9 Bioscience is working to change that. Learn more at darebioscience.com<\/a>.<\/p>\n

\n
\n FORWARD-LOOKING STATEMENTS<\/u>
\n <\/strong>\n <\/p>\n

Dar\u00e9 Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cprepare,\u201d \u201cprogress,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cbuild,\u201d \u201cexplore,\u201d or the negative version of these words and similar expressions.<\/p>\n

In this press release, forward-looking statements include, but are not limited to, statements relating to: DARE-LARC1\u2019s potential as a safe and effective long-acting reversible contraceptive product; continued development of DARE-LARC1; future submission of an IND application for DARE-LARC1; use of the funding installment received and potential for Dar\u00e9 Bioscience to receive additional funding under the grant agreement relating to DARE-LARC1; the potential capabilities of DARE-IDDS as part of a therapeutic product for humans, including storing and delivering discrete doses over periods ranging from months to years and electronic dose programming; the potential application of DARE-IDDS in a broad range of therapeutic areas, including obesity, diabetes, breast cancer, infertility, and Parkinson\u2019s disease; the potential of DARE-IDDS to improve treatment adherence and reduce treatment burden; and the potential for Dar\u00e9 Bioscience to enter into strategic collaborations for application of DARE-IDDS outside of contraception, including in large chronic disease markets.<\/p>\n

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dar\u00e9 Bioscience\u2019s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: advancing DARE-LARC1 and any future product candidate utilizing DARE-IDDS through preclinical stage development and into human clinical trials; the ability of product candidates utilizing DARE-IDDS to demonstrate acceptable safety, tolerability and efficacy, including contraceptive effectiveness, in humans; the potential that product candidates utilizing DARE-IDDS may not demonstrate the dose capacity, duration of drug storage and delivery, or wireless connectivity and remote treatment monitoring and adjustment functionality anticipated based on technological proof-of-concept studies of DARE-IDDS; the risk that positive findings in technological proof-of-concept studies, other nonclinical studies and\/or early clinical studies of a product candidate may not be predictive of success in subsequent clinical and\/or nonclinical studies of that candidate; delays, increased costs, or failure in completing necessary nonclinical and clinical studies of a product candidate, including due to unanticipated requirements for additional testing; potentially more complex, costly or lengthy development and approval requirements for drug-device combination product candidates; delays or failure to obtain U.S. Food and Drug Administration (FDA) or foreign regulatory approval for a product candidate; achieving anticipated treatment adherence or reduction in treatment burden benefits with any DARE-IDDS-based product, if approved; difficulties establishing and maintaining relationships with development and\/or commercial collaborators; Dar\u00e9 Bioscience’s dependence on third parties to conduct nonclinical and clinical studies and manufacture and supply clinical trial material and commercial product, and the performance and resource commitments of such third parties; difficulties in manufacturing drug product candidates and their components at the required quality, stability and scale for clinical trials and commercialization; Dar\u00e9 Bioscience’s ability to obtain additional capital when and as needed to execute its business strategy and continue as a going concern; dependence on grants and other financial awards from governmental entities and a private foundation and the risk that such funding may be reduced, delayed, or terminated, or may be insufficient to advance a product candidate into or through a particular stage of development as anticipated; Dar\u00e9 Bioscience’s ability to achieve the milestones and meet other requirements to receive additional funding under the grant agreement; potential suspension and delisting of Dar\u00e9 Bioscience’s common stock from The Nasdaq Capital Market; failure of any products, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; the risk that developments by competitors make Dar\u00e9 Bioscience’s products or product candidates less competitive or obsolete; Dar\u00e9 Bioscience’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Dar\u00e9 Bioscience’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Dar\u00e9 Bioscience’s ability to adequately protect or enforce its, or its licensor\u2019s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Dar\u00e9 Bioscience’s product candidates, which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Dar\u00e9 Bioscience’s products or product candidates or the business activities of Dar\u00e9 Bioscience, its commercial collaborators or other third parties on which Dar\u00e9 Bioscience relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Dar\u00e9 Bioscience’s ability to raise additional capital or on Dar\u00e9 Bioscience’s operations, financial results and condition, and ability to achieve current plans and objectives; and cybersecurity incidents or similar events that compromise Dar\u00e9 Bioscience’s technology systems and\/or significantly disrupt Dar\u00e9 Bioscience’s business or those of third parties on which Dar\u00e9 Bioscience relies.<\/p>\n

Dar\u00e9 Bioscience\u2019s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Dar\u00e9 Bioscience\u2019s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including Dar\u00e9 Bioscience\u2019s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Dar\u00e9 Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n

\n Contact:<\/strong>
\n
\n Dar\u00e9 Bioscience Investor Relations<\/strong>
\n
\n innovations@darebioscience.com<\/a>\n <\/p>\n

\n Source: Dar\u00e9 Bioscience, Inc.<\/em>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development\u00a0 Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes and Other Large Chronic-Disease Markets SAN DIEGO, Oct. 30, 2026 (GLOBE NEWSWIRE) — Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced receipt of an additional $1.5 million funding installment under its multi-year grant agreement in support of development of DARE-LARC1, an investigational long-acting reversible contraceptive based on Dar\u00e9 Bioscience’s intelligent drug delivery system (DARE-IDDS) platform. With this installment, Dar\u00e9 Bioscience has received a total of approximately $43.3 million in non-dilutive funding under the grant agreement. The … <\/p>\n

Continue reading “Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1015760","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development\u00a0 Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes and Other Large Chronic-Disease Markets SAN DIEGO, Oct. 30, 2026 (GLOBE NEWSWIRE) — Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced receipt of an additional $1.5 million funding installment under its multi-year grant agreement in support of development of DARE-LARC1, an investigational long-acting reversible contraceptive based on Dar\u00e9 Bioscience’s intelligent drug delivery system (DARE-IDDS) platform. With this installment, Dar\u00e9 Bioscience has received a total of approximately $43.3 million in non-dilutive funding under the grant agreement. The … Continue reading "Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-30T12:41:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjYwMiM3OTI1NTMyIzIwMDgzNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum\",\"datePublished\":\"2026-10-30T12:41:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/\"},\"wordCount\":1809,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjYwMiM3OTI1NTMyIzIwMDgzNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/\",\"name\":\"Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjYwMiM3OTI1NTMyIzIwMDgzNjQ=\",\"datePublished\":\"2026-10-30T12:41:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjYwMiM3OTI1NTMyIzIwMDgzNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjYwMiM3OTI1NTMyIzIwMDgzNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/","og_locale":"en_US","og_type":"article","og_title":"Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum - Market Newsdesk","og_description":"Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development\u00a0 Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes and Other Large Chronic-Disease Markets SAN DIEGO, Oct. 30, 2026 (GLOBE NEWSWIRE) — Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced receipt of an additional $1.5 million funding installment under its multi-year grant agreement in support of development of DARE-LARC1, an investigational long-acting reversible contraceptive based on Dar\u00e9 Bioscience’s intelligent drug delivery system (DARE-IDDS) platform. With this installment, Dar\u00e9 Bioscience has received a total of approximately $43.3 million in non-dilutive funding under the grant agreement. The … Continue reading \"Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-30T12:41:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjYwMiM3OTI1NTMyIzIwMDgzNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum","datePublished":"2026-10-30T12:41:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/"},"wordCount":1809,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjYwMiM3OTI1NTMyIzIwMDgzNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/","name":"Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjYwMiM3OTI1NTMyIzIwMDgzNjQ=","datePublished":"2026-10-30T12:41:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjYwMiM3OTI1NTMyIzIwMDgzNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjYwMiM3OTI1NTMyIzIwMDgzNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-surpasses-43-million-in-non-dilutive-grant-funding-as-investigational-programmable-drug-delivery-platform-gains-momentum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dar\u00e9 Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1015760"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015760\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1015760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1015760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1015760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}